Pmv Pharmaceuticals Inc (PMVP NASDAQ) stock market data APIs
$1.4
0.05(3.7%)
as of January 14, 2025
Pmv Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Prev. Close
1.35
Open
1.4
Volume
190 K
High
1.5
Low
1.35
52 wk Range
1.35-2.26
Market Cap
69 859 K
Shares Outstanding
51 747 K
Revenue
0
EPS
-0.37
Beta
1.484
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pmv Pharmaceuticals Inc data using free add-ons & libraries
Get Pmv Pharmaceuticals Inc Fundamental Data
Pmv Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 0
- EBITDA: -77 121 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pmv Pharmaceuticals Inc News
New
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
PMV Pharmaceuticals, Inc. Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30% Unaudited cash, cash equivalents, and mar...
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
PMV Pharmaceuticals, Inc. PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Me...
PMV Pharmaceuticals Inc (PMVP) Reports Q3 2023 Financial Results and Corporate Updates
PMV Pharmaceuticals Inc (NASDAQ:PMVP) presented updated data from Phase 1 PYNNACLE clinical trial, showing promising responses across multiple tumor types. PMVP reported a net loss of $53.2 million fo...
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
PMV Pharmaceuticals, Inc. Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstra...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
